eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2022
vol. 26
 
Share:
Share:
abstract:
Letter to the Editor

A long-term responding epidermal growth factor receptor mutated non-small cell lung cancer patient with extremely high mutation allele frequency

Kunihiko Miyazaki
1
,
Yoshiharu Sato
2
,
Hiroaki Satoh
3
,
Nobuyuki Hizawa
4

1.
Ryugasaki Saiseikai Hospital, Japan
2.
DNA Chip Research Inc., Tokyo, Japan
3.
Mito Medical Center, University of Tsukuba, Japan
4.
Faculty of Clinical Medicine, University of Tsukuba, Japan
Contemp Oncol (Pozn) 2022; 26 (1): 88–89
Online publish date: 2022/03/30
View full text Get citation
 
PlumX metrics:
Epidermal growth factor receptor (EGFR) mutation is the most frequent oncogenic driver in non-small cell lung cancer (NSCLC) [1, 2]. Among EGFR mutations, exon 19 deletion and exon 21 L858R are two of the most common mutations; hence they are referred to as common mutations [1]. In addition to them, there are many types of EGFR mutation other than common mutations. They are treated as uncommon mutations [3, 4]. Recent advances in analysis technology using next-generation sequencing (NGS) have made great progress also in the area of EGFR mutation [5–8]. By this analytic method, it has become clear that there is heterogeneity among patients with common mutations. Among these possible heterogeneities, mutation allele frequency (MAF) has drawn attention [9–13]. MAF is defined as the number of times a mutated base is observed, divided by the total number of times any base is observed at the locus. It corresponds to the percentage of sequencing reads that contain the mutation, and the proportion of alleles is affected by the proportion of tumor cells in the sample and the presence of copy number alterations [9–13]. Here we report a case of a patient with EGFR mutation with very high MAF, who responded to EGFR-tyrosine kinases for a long time.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.